Enzon Pharmaceuticals, Inc. (ENZN) - NASDAQ
  • Mar. 19, 2013, 6:39 AM
    Enzon Pharmaceuticals (ENZN): Q4 EPS of -$0.11. Revenue of $10.6M. (PR)
    | Mar. 19, 2013, 6:39 AM
Company Description
Enzon Pharmaceuticals, Inc. operates as a biopharmaceutical company. It receives royalty revenues from existing licensing agreements with other companies primarily related to sales of four marketed drug products namely PegIntron, Sylatron, Macugen, and CIMZIA. The company was founded by Abraham... More
Sector: Healthcare
Industry: Biotechnology
Country: United States